Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Vaccine waiver talks can make drug firms the heroes, U.S. trade chief says

Published 12/05/2021, 21:07
Updated 12/05/2021, 21:10
© Reuters. FILE PHOTO: U.S. Trade Representative Katherine Tai testifies before a Senate Appropriations subcommittee during a hearing on Capitol Hill, in Washington, U.S., April 28, 2021. Sarah Silbiger/Pool via REUTERS/File Photo/File Photo

By David Lawder

WASHINGTON (Reuters) - U.S. Trade Representative Katherine Tai said on Wednesday she is pushing for a waiver of COVID-19 vaccine intellectual property rights because the United States and drug makers have "an obligation to help save the world right now."

Tai, speaking at a U.S. Senate Finance Committee hearing, said she views the World Trade Organization talks as a way to remove the intellectual property issue as an obstacle to vaccine production. She backed the WTO negotiations last week.

She praised the work of U.S. companies in quickly developing and producing safe and effective vaccines, adding that on intellectual property, "The message that I want to give to them is, 'You can be a hero here.'"

Several Republican senators criticized Tai for "giving away" U.S. innovations to foreign competitors by supporting the WTO negotiations.

Tai said she views the talks to be less about preventing other countries from "stealing" U.S. technology and more about finding a way to have a positive impact on people's lives by ending the coronavirus pandemic.

"What we are trying to accomplish is the saving of lives," she said, adding that ending the pandemic is a necessary first step in any trade policy going forward.

"Unless we are able to bring the rest of the world's economies back online, there's not going to be a lot of upside for us in what we're going to be doing" on trade, Tai said.

India is experiencing a pandemic tragedy of "unimaginable scale" and South Africa, the other main proponent of vaccine waivers, has no facilities to produce vaccines and would need them to end the pandemic on the African continent, Tai said.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Negotiations at the WTO will take time, with a process for negotiations just starting now, Tai added.

She added that she did not see waiver talks as leading to a "slippery slope" of a broader erosion of intellectual property rights, as the current crisis is unique and threatening millions of lives. Such waivers on clean energy technologies would not be necessary to fight the crisis of climate change, Tai said.

Asked by Democratic Senator Elizabeth Warren whether USTR would support a broader WTO intellectual property waiver on COVID-19 treatments, therapeutics, protective equipment and other medical products, Tai said she is currently only focused on increasing vaccine access and equity.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.